The ability of the E6 protein from high risk human papillomaviruses (HPVs) to degrade p53 via the ubiquitin pathway plays a major role in the development of cervical carcinomas. We have previously generated cell hybrids between a p53 null peripheral neuroepithelioma (PNET) cell line and a cervical carcinoma HeLa cell line which exhibits ecient E6-mediated degradation of p53. All of the resulting hybrids expressed HPV 18 E6 from the HeLa parent and some of the hybrids additionally expressed HPV 16 E6. Surprisingly, in spite of abundant E6 expression, the hybrids expressed relatively high steady-state levels of the wild-type p53 protein. We then examined the hybrids to determine whether other components of the E6-mediated degradation pathway were missing or nonfunctional. Speci®cally, we determined that the E6-associated protein (E6-AP), essential for E6-mediated degradation, was expressed. We further veri®ed that these hybrids had a functional ubiquitination pathway, which suggests that this phenomenon is not due to a general defect in this pathway. We therefore conclude that other unidenti®ed, possibly cellspeci®c factors can play a role in the E6-mediated degradative process and may act to inhibit this process.
Introduction
Inactivation of tumor suppressor gene function is often a primary event in the multistep process of carcinogenesis. One eective means of delineating the genetic basis of tumorigenicity is to de®ne complementation groups by creating cell hybrids from tumorigenic parents originating from dierent developmental lineages (Weissman, 1990; Weissman and Stanbridge, 1983) . This technique has proved particularly useful in determining whether dierent tumor cells share common defective tumor suppressor genes. To investigate complementation groups for tumorigenicity, we previously created cell hybrids between a peripheral neuroepithelioma (PNET) cell line and a HeLa cell line . The evidence had suggested that p53, one of the most important tumor suppressors identi®ed thus far, (Hollenstein et al., 1991; Vogelstein and Kinzler, 1992) , was not the operative tumor suppressor gene in the cell lines assayed, as introduction of a chromosome 17 containing mutant or no p53 was able to suppress tumorigenicity of the recipient cells . Creation of the HPV E6 containing hybrids was meant to provide further evidence for the existence of a second tumor suppressor on chromosome 17, as human papillomavirus (HPV) DNA derived from the HeLa parents was expected to inactivate p53 function and facilitate degradation of the protein Schener et al., 1990; Werness et al., 1990) .
The human papillomaviruses play a major role in cervical carcinomas, as evidenced by the fact that high risk HPV DNA (HPV 16, 18) is found in at least 90% of all cases (Lowry et al., 1994) . This contrasts with low risk HPVs, which are not associated with malignant progression. The biochemical basis for the dierence in HPV risk classi®cation is strongly correlated with the ability of the 18 kD HPV E6 protein to bind and target p53 for degradation . The half-life of wild type p53 is normally short in primary cells (between 5 ± 40 min) (Oren et al., 1981) and its degradation has been shown to involve ubiquitin-dependent proteolysis (Blumenfeld et al., 1994; Chowdary et al., 1994) . The high risk HPV E6 protein has the ability to associate with wild type p53, targeting the protein for rapid degradation via the ubiquitin pathway. The E6 protein acts in concert with a 100 kD E6-associated protein (E6-AP) (Huibregtse et al., 1991 (Huibregtse et al., , 1993a ) that together function as a ubiquitin protein ligase (Huibregtse et al., 1993b; Schener et al., 1993) to signal the ubiquitination and degradation of p53. Complex formation between E6 and E6-AP is necessary for its high anity binding and subsequent degradation of p53. E6 proteins from the low risk HPV forms cannot target p53 for degradation as a consequence of their inability to signi®cantly bind E6-AP.
Although neither of the parental cell lines exhibited signi®cant p53 protein expression, during preliminary studies we observed high steady-state levels of p53 in the hybrids, despite the expression of HPV proteins. This unexpected observation precipitated the present study, which examines the functional status of p53 in the PNET6HeLa hybrids, as well as possible mechanisms involved in the stability of p53 protein levels.
In this report, we ®rst veri®ed that all of the previously identi®ed components associated with the E6 degradative pathway were present in the PNET6HeLa hybrid cells. Speci®cally, we determined both E6 and E6-AP were expressed in these cell lines. In addition, we analysed the functionality of the ubiquitin pathway by examining the degradation of cjun, which serves as an additional substrate of the ubiquitin pathway (Treier et al., 1994) . The data suggest that the inability of E6 to degrade p53 in these cell lines is a phenomenon due speci®cally to a modulation of the E6-mediated degradation pathway, rather than to a general defect in the ubiquitination pathway. Taken together, the data suggest that several normal functions of p53 in the hybrids remains inactivated, either by E6 or by another cellular protein, and that the E6-mediated degradative process in these cell lines is compromised relative to the HeLa parent. We therefore propose that additional cellular proteins are able to modulate the interaction between E6 and p53.
Results
The HPV 18 E6 containing cell hybrids retain high levels of p53 protein expression Because it has been well established that the high risk E6 proteins eciently target p53 for degradation Schener 1990 ) we wanted to verify that the E6 protein from the PNET6HeLa hybrids would be able to degrade p53 in the hybrid cells as well. As outlined in the Introduction, this would further serve to prove that p53 is not the operative tumor suppressor gene in the cell lines assayed, including the PNET6HeLa hybrids. As previously mentioned (and shown in Figure 1) , neither of the parental cell lines demonstrate signi®cant expression of p53 protein. Unexpectedly, the HPV 18 E6 containing hybrids HHy78 P1 and P2 displayed relatively high levels of p53 protein expression, as shown in Figure 1 and summarized in Table 1 . Western blot analysis revealed that steadystate p53 levels in the hybrids were comparable to or higher than that seen for the normal human ®broblast cell line GM2291, which was used as a reference for p53 expression. Because the levels of HPV 18 E6 RNA were somewhat lower in the hybrids relative to the HeLa parent (see below and Figure 2a) , we created the hybrid series HHy79 P1 ± P3, which contains additional HPV 16 E6, due to stable transfection of this gene. These hybrids should then contain an excess of E6 sucient to degrade p53. As shown in Figure 1 and summarized in Table 1 NHF ®broblasts infected with a HPV 16 E6 retrovirus were used as a comparison for E6 message levels eect on the steady state levels of p53, which was veri®ed by densitometry. By contrast, the HeLa derived parental cell line D98 had barely detectable levels of p53 protein, indicating that p53 was eciently degraded by E6 in this cell line. The PNET parent, A673, does not express p53 protein or RNA (Figures 1  and 3 ).
The hybrids contain normal levels of wild type p53 message
Because endogenous E6 levels are low, the protein must act catalytically to degrade all of the p53 protein . However, it seemed possible that an excess of p53 might saturate the E6-mediated degradation reaction. To determine if the observed p53 protein expression was due to an overexpression of the transcript, we examined the levels of p53 message. As shown in Figure 3 , all of the hybrids contain similar levels of p53 mRNA. These levels are comparable to those of GM2291 and to the HeLa derived D98
OR . Since E6 degrades almost all of the p53 protein in the HeLa cell line, as well as in GM2291 (data not shown), and because the p53 message levels are similar, it is evident that the p53 message levels in the hybrids are not excessive. Because E6 eciently targets p53 for degradation in the HeLa cell line and the p53 message levels in the hybrids are comparable, E6 should similarly target p53 in the hybrids for rapid degradation.
One obvious explanation for the lack of p53 degradation in the hybrid cell lines could be the acquisition of p53 mutations during the fusion process. Although no examples of this phenomenon exist in the literature, we analysed the sequence of the p53 gene for mutations in the three original HHy78 hybrids cells as well as the newer HHy79 cell lines. The complete sequence of exons 4 ± 9 in the HeLa parent and all microcell hybrids proved wildtype as determined by cycle sequencing. In addition, we performed SSCP analysis of all 11 exons and found no abnormalities (data not shown) (Mashiyama et al., 1991) . Although these techniques might miss up to 5% of unusual mutations found in exons 1 ± 3 and 11, the frequency of this event in six independently-arising hybrid cell lines is 51610 7 ((0.05) 6 ). Therefore, the p53 genes in the hybrid cells encode a wild type protein, presumably subject to degradation in the presence of the E6 protein.
E6 protein is expressed in the hybrid cell lines
It was possible that the high levels of p53 protein observed in the hybrids was due to an inability of the cells to express adequate amounts of E6 protein. Therefore, Northern analysis was used to examine levels of the E6 transcript. As shown in Figure 2a , all of the hybrid cell lines express both splice variants of HPV 18 E6 (Bernard, 1993) derived from the parental cell line D98. The relative amounts of message were normalized with actin. It can be seen that the hybrids all express detectable levels of HPV 18 E6 RNA. Although the levels in the hybrids are somewhat lower compared to D98 OR , adequate protein was detected in these cell lines (see below). Hybrids HHy79 P1-P3 additionally express HPV 16 E6 RNA from the stably transfected HPV 16 E6 gene. As shown in Figure 2b , the level of HPV 16 E6 RNA in these hybrids was comparable to that of NHF-E6, human ®broblasts infected with a retroviral HPV 16 E6 construct. NHF-E6 cells do not have detectable amounts of p53 protein (data not shown), indicating ecient degradation by HPV 16 E6 at these levels. Therefore, compared to NHF-E6, sucient levels of E6 message exist in the hybrids for the protein to eciently target p53 for degradation.
To ensure ecient translation, we examined E6 protein levels using immuno¯uorescence, due to the inherent diculties in visualizing the protein by immunoprecipitation (Liang et al., 1993) . As shown in Figure 4 , immuno¯uorescence with the HPV 16/18 E6 antibody was speci®c for E6, as it did not react with E6-negative NHF ®broblasts (a), osteosarcoma SAOS-2 cells (b), or NHFs expressing HPV 16 E7 (c). In contrast, the antibody reacted with NHF-E6 (d) and D98 (e), used as positive controls for HPV 16 and 18 E6, respectively. After verifying the speci®city of the E6 antibody, the hybrid cell lines were tested for E6 expression. As shown in Figure 4f ± i, the hybrid cell lines were all strongly positive for E6 expression and displayed a characteristic cytoplasmic distribution. The apparently lower¯uorescence intensity in the hybrids compared to D98 OR can be accounted for by their larger cytoplasmic area, resulting in a diused signal. In addition, it appears that the antibody has a higher anity for HPV 18 E6 than HPV 16 E6 (compare d and e), which could explain why the HHy79 hybrids do not appear to have signi®cantly more E6 protein compared to the HHy78 hybrids. The¯uorescence data do not show any signi®cant reduction in E6 protein levels, as was suggested by the HPV 18 E6 Northern data. This implies that either E6 translation eciency is not directly proportional to the amount of message, or that regardless of the message levels, there is an upper limit of E6 protein produced. The hybrids appear to contain similar amounts of E6 protein as seen in NHF-E6, although they might dier by as much as two-to threefold. Since p53 is degraded in
The cell hybrids do not overexpress p53 message. Total RNA was isolated from 5610 6 cells. Ten mg was size fractionated on a 1.0% agarose/formaldehyde gel, transferred to nylon membrane, and sequentially probed with p53 and actin probes. The full length 1.8 kb p53 cDNA was used as a probe in a random primed reaction as described. A673BrdU lacks p53 message these cells , it appears that the levels of E6 protein in the hybrids are sucient to mediate the degradation of p53. Based on these observations, we conclude that although the hybrid cells express sucient E6 mRNA and protein, the protein cannot eciently degrade p53.
E6-AP is expressed in the hybrid cell lines
We examined whether any other known proteins of the E6-mediated degradation pathway were absent in the hybrids. Previous studies have demonstrated that the E6 protein acts in concert with a 100 kD E6 associated protein (E6-AP) (Huibregtse et al., 1991 (Huibregtse et al., , 1993b to signal the ubiquitination and degradation of p53. Complex formation between E6 and E6-AP is essential for its high anity binding to p53. E6-AP expression has been detected in all cell lines tested thus far. We therefore wanted to verify that E6-AP was expressed in the cell hybrids. We chose Northern analysis, as no commercial antibodies to this protein are currently available. As shown in Figure 5 , all of the cell hybrids express the 5 kb E6-AP transcript. Furthermore, the E6-AP RNA levels are comparable in all of the cell lines. Therefore, the inability of E6 to degrade p53 is not likely due to a limiting amount of E6-AP expression.
The p53 protein from the HPV E6 containing hybrids possesses an increased half-life
Although the half-life of p53 is somewhat variable, depending on the cell type and environment, the most The cell hybrids express the E6-associated protein (E6-AP). The blot in Figure 2a was stripped and reprobed with a 0.5 kb PCR generated 32 P-labelled E6-AP probe. The 5 kb transcript corresponding to E6-AP is indicated. The same blot was stripped and normalized to B-actin commonly reported range falls between 10 min to less than 1 h (Oren et al., 1981) . The E6 protein targets p53 for degradation in vitro, reducing its half-life several fold (Schener et al., 1990) . We therefore examined whether the E6 protein present in the hybrid cell lines similarly resulted in a short-lived p53 protein. Cells were metabolically labeled and then subjected to pulsechase analysis. The p53 protein was evident as a doublet in these experiments. As shown in Figure 6 , and summarized in Table 2, p53 from the HeLaderived D98 OR displayed degradation kinetics consistent with what has been reported for p53 in HPV infected cells, with a half-life between 5 ± 10 min. In contrast, p53 in the HHy78 hybrids had a half-life between 30 ± 40 min, comparable to published reports of the stability of the wild type protein in many cell types in the absence of E6. In addition, there were detectable levels of protein in the hybrids even after 90 min of chase. Furthermore, although p53 from the HHy79 hybrids, which contain both HPV 16 and 18 E6 proteins, had a slightly reduced half-life relative to the HHy78 hybrids, p53 degradation was still not as ecient as in D98
OR (compare 15 and 30 min time points Table 3 ). Although the introduction of HPV 16 E6 into the hybrids decreased p53 stability relative to the HHy78 hybrids, its half-life in the HHy79 hybrids was consistently at least twice as long as that observed for the HPV 18 E6 containing D98 OR . These results suggest that HPV 16 E6 was not as ecient at degrading p53 in the hybrids.
Inecient E6-mediated p53 degradation is not due to a general defect in the ubiquitin pathway The p53 protein is degraded via the ubiquitin pathway, which is also responsible for regulating the stability of other short-lived oncoproteins such as fos, myc, and cjun (Ciechanover 1991; Treier et al., 1994) . Since the half-life of p53 in the hybrids was longer than what is observed for HPV positive cells, we investigated whether the increased stability of the protein arose from a general defect in the ubiquitin pathway. This seemed unlikely, as deregulated turnover of cellular proteins would likely lead to cell death. Since c-jun has recently been identi®ed as a substrate for the ubiquitin pathway, we decided to determine its half-life in the hybrids as a test for a general defect of this pathway. A pulse-chase experiment similar to that for p53 was performed, followed by immunoprecipitation with a cjun speci®c antibody. The half-life for c-jun has been reported to be approximately 90 min (Treier et al., 1994) . As shown in Figure 7 , the half-life of c-jun in a representative hybrid cell line is comparable to that observed in the parental A673BrdU and in D98 OR . In all the cell lines, the levels of c-Jun are markedly reduced 8 TCA precipitable counts were immunoprecipitated overnight with the p53 speci®c antibody DO-1. Immunoprecipitates were washed with a 1% NP-40/0.1% SDS wash buer, boiled in denaturing Laemmli buer, and run on a 10% polyacrylamide gel. The gels were ®xed, enhanced, dried, and exposed to ®lm at 7808C. Typical exposure time was 12 h. Half-life determination was calculated by phosphorimager analysis of the labelled blots by 3 h and are barely detectable by 5 h. This indicates that the hybrids are able to eciently target proteins for degradation, that the 26S ubiquitin-proteasome complex (Eytan et al., 1989 ) is functional, and that the hybrids do not have a general defect in their ubiquitin pathway.
The activity of p53 in the hybrids does not increase following irradiation
The above experiments showed that the E6 proteins were not eciently degrading p53, therefore, we asked whether the p53 protein might retain wild type activity. One of the major roles of p53 is its ability to modulate the cell cycle in response to DNA damage (Hall et al., 1993; Kastan et al., 1992; Kuerbitz et al., 1992) . As such, we examined whether the p53 present in the hybrids was able to mediate a response to DNA damage. To address this question, we administered 450 Rads to the cells with a cesium source and measured p53 levels at 2 h post IR, the reported time for maximal induction (Kastan et al., 1991) . As shown in Figure 8a , the ®broblast cell line GM2291 demonstrated a marked increase in the p53 protein levels following IR, indicative of a functional protein. In contrast, neither p53 from the parental D98 OR nor from the hybrid cell lines showed any increase in p53 levels in response to DNA damage. This suggests that p53 protein in the hybrids does not function in this context.
To investigate whether p53 demonstrated any biological activity in response to IR, we examined its ability to transactivate p21, a known inhibitor of the cell cycle (El-Deiry et al, 1993; Harper et al., 1993; Xiong et al., 1993) . It has been previously reported (Li et al., 1994 ) that p21 levels are maximal 18 ± 20 h post IR. We therefore irradiated the cells as before, lysed them after 18 h and subjected them to Western analysis with a p21 speci®c antibody. As shown in Figure 8b , basal p21 levels, barely detectable in the ®broblast cell line GM2291 before IR, rose several fold post irradiation. In contrast, neither D98 nor any of the hybrid cell lines were able to induce p21 protein expression. SAOS-2 cells, which lack endogenous p53 (Masuda et al., 1987) , were used as an additional negative control.
The failure of cells to regulate p21 usually results in the abrogation of the G 1 checkpoint. We therefore investigated whether the p21 data correlated with an inability of the hybrids to G 1 arrest following IR. Using¯ow cytometry (data not shown), we have found that following irradiation, neither the parental nor hybrid cell lines were able to mediate a G 1 arrest, consistent with the lack of signi®cant levels of p53 protein in the parental lines. Thus, despite the high protein levels and relative stability of p53 in the hybrids, the protein was still unable to retain any activation function (see Discussion). Because the data show that p53 levels do not increase following IR, that p53 cannot transactivate p21, and that p53 could not induce cell cycle arrest, it appears that the p53 present in the hybrid cell lines does not possess several wild type functions.
Discussion
In this report we showed that cell hybrids between two parental lines that do not express p53 exhibit high steady-state levels of p53 expression despite the presence of HPV E6. The increased expression appears partly due to a longer half-life of the protein, despite the presence of HPV E6. In fact, the half-life of p53 in the hybrids was comparable to the protein in the cells lacking E6 expression. The stability and expression of cells were plated and one set was exposed to 450 Rad IR. (a) 2 h post IR both sets were lysed, quantitated, and 15 mg lysate was separated by 10% SDS ± PAGE and subjected to Western analysis as described in Figure 1 . Normal human ®broblasts (GM2291) were used as a positive control for p53 induction. (b) Two additional sets of cells were similarly plated. One set was treated with the same dose of IR and both sets were lysed 20 h post IR. Seventy mg protein was separated by 15% SDS ± PAGE and subjected to Western analysis with a p21 speci®c antibody. GM2291 ®broblasts were used as a positive control for wild type p53 activity, while p53 null SAOS-2 cells were used as a negative control p53 in the presence of E6 did not arise from a mutant protein, a general defect in the ubiquitin pathway, or a lack of E6-AP expression. A previous report has shown that the HHy78 hybrids have lost the ability to undergo gene ampli®cation, a process controlled in part by wild type p53 protein (Hall et al., 1996) . However, the stable, genotypically wild type protein was not completely functional, as assayed by several other parameters. Therefore, our data show that the presence of HPV E6 does not ensure the complete degradation of wild type p53 as observed in other cell types.
One possible explanation for our results could arise from the preferential selection during the cell fusion process for a minor population of cells that possess mutations in p53 or E6-AP. While this scenario might seem like a reasonable caveat, the frequency of hybrid formation eliminates this concern. Under the best circumstances, the rate of viable cells hybrid production after cell fusion peaks at 1610
74
. In our experiments, our cell fusion protocol yields viable hybrids at a frequency of about 1610
75
. Therefore, if as many as 1% of the D98 OR cell lines possessed a mutant p53 or E6-AP protein, the hybrids would appear at a frequency of 1610 77 or less, a number inconsistent with our observed results.
We suggest that additional cellular factors can modulate the E6-mediated degradation of p53 and oer two mechanisms by which such factors may operate. In the ®rst, E6/E6-AP protein interactions with p53 are dependent on p53 conformation. It has previously been shown that E6 preferentially targets p53 for degradation upon presentation of the 1620 epitope (Medcalf and Milner, 1993) , which represents the wild type, suppressor conformation of p53 (Donnehower and Bradley, 1993; Oren, 1992) . It is not known how presentation of this epitope is regulated, but it is likely that the cellular environment (Hainaut and Milner, 1993) , cellular factors (Hainaut and Milner, 1992) , and phosphorylation (Landesman et al., 1994; Meek, 1994) of p53 are involved.
It is becoming apparent that in addition to the various conformations of p53 detected by epitopespeci®c antibodies, the p53 protein is composed of a multitude of isoforms (Selkirk et al., 1994) . Undoubtedly, these dierent isoforms in¯uence both the activity and stability of the protein (Maxwell and Roth, 1994; Milner, 1994) . This may re¯ect a mechanism by which dierent cell types can regulate p53 function such that specialized functions of p53 will result in various p53 subpopulations. Such a scenario has been used to explain the varying epitope reactivities observed during keratinocyte dierentiation (Spandau, 1994) . Since E6-mediated degradation of p53 may be dependent upon p53 conformation, it is likely that the susceptibility of p53 to degradation in any given cell will vary depending upon the prevailing subpopulation.
A second mechanism for attenuating E6-mediated p53 degradation would involve the cellular environment and/or cell-speci®c factors that interact with p53 and interfere with E6/E6-AP-p53 complex formation. The existence of such factors are substantiated by reports that show the cellular environment can in¯uence both p53 stability and function. For example, wild type p53 can exist as a stabilized protein in the absence of mutations or stabilizing viral proteins in diverse cellular environments such as lymphomas (Lee et al., 1994; Villuendas et al., 1993) ®brosarcomas (Halevy et al., 1989) , gliomas (Anker et al., 1993) , and colorectal carcinomas and adenomas (Cripps et al., 1994; Tominaga et al., 1993) . The cellular context can also in¯uence p53 stability separate from the process of transformation, as observed in normal human mammary epithelial cells and human keratinocytes (Delmolino et al., 1993; Gudas et al., 1994; Lechner et al., 1992; Sedman et al., 1992) .
The theory that dierent p53 subpopulations and cellular contexts can modulate the susceptibility of p53 to E6-mediated degradation would explain contradictory reports. For instance, increasing evidence clearly suggests that the expression of E6 does not necessarily equate to a p53 null background. It was demonstrated (Fouret et al., 1995; Tervahauta et al., 1994 ) that a substantial proportion of HPV positive cervical carcinomas are also p53 positive. Similar irregularities have been found in vitro , in that introduction of E6 can alter p53 half-life without signi®cantly reducing steady-state levels. We are presently investigating whether p53 subpopulations in our cell hybrids have varying susceptibilities to E6-mediated p53 degradation.
From the evidence demonstrating the in¯uence of the cellular environment upon p53 stability, one might hypothesize that cell-speci®c factors aect the ability of E6 to target p53 for degradation. For example, it has been reported (Chen and Defendi, 1992) that HPV E6 has only a marginal eect on abrogating the suppression activity of murine p53, partly attributed to its inability to eectively reduce the half-life of p53 in NIH3T3 cells . In contrast to NIH3T3 cells, Sedman et al. (1992) observed ecient degradation of p53 by HPV 16 E6 in human keratinocytes. Yet keratinocytes immortalized by E6 were found to have variable amounts of p53 . Finally, although E6 has the ability to disrupt p53-DNA complexes in vitro (Thomas et al., 1995) , Butz et al. (1995) demonstrated wild type p53 from HPV infected cell lines retain varying levels of wild type activity. These ®ndings further suggest that the ability of E6 to degrade p53 and abrogate its function can vary among cell lines.
We hypothesize that dierent cellular backgrounds may modulate the interaction of cellular proteins with p53, resulting in varying anities of E6 for p53. Further support for cell-speci®c factors is provided by our experimental observations. The inability of E6 to rapidly degrade p53 in the hybrids did not arise from the creation of the hybrids themselves, as a cell hybrid between HeLa6keratinocytes exhibited ecient degradation of the p53 protein (data not shown). The ability of E6 from the HeLa parent to eciently degrade p53 suggests that the hybrids should contain the necessary degradation machinery, including functional ubiquitin enzymes. Several known cellular proteins bind p53 and aect its activity and stability, such as mdm-2 (Momand et al., 1992) . However, mdm-2 does not aect E6-mediated degradation (Marston et al., 1994) . Most recently, it was demonstrated (Maheswaran et al., 1995) that the WT1 protein interacts with p53 and interferes with E6-mediated degradation of p53.
Our model system oers direct evidence that the cellular background can modulate the process of E6-mediated p53 degradation. It seems probable that additional, possibly unidenti®ed cellular factors in the hybrids attenuate the process of E6-mediated degradation in a similar fashion to the kidney speci®c WT1. Of particular interest is the fact that the hybrids derive from a neuronal parent. The activity and stability of p53 in normal neuronal cells remains poorly characterized, due to the paucity of such established cell lines. Furthermore, the eects of E6 expression and/or p53 stability in neuronal cell lines has not been examined. We therefore plan to use our system to identify additional cell-speci®c factors capable of interacting with p53 and modulating the E6-mediated degradative process.
Materials and methods

Cell culture
Cell lines, unless speci®ed, were grown in RPMI 1640 supplemented with 10% fetal bovine serum and penicillin/ streptomycin. The hybrid series HHy78 and HHy79 were grown in RPMI supplemented with 600 mg/ml geneticin, 1610 77 M ouabain, and hypoxanthine-aminopterin-thymidine (HAT). The ouabain-resistant, HPRT 7 HeLa cell derivative D98 OR (Weissman and Stanbridge, 1980) was cultured in RPMI supplemented with 1610 77 M ouabain. The peripheral neuroepithelioma (PNET) parent was a thymidine kinase-de®cient (TK 7 ) clone of the cell line A673, designated A673BrdU (Giard et al., 1974) . A673BrdU-16 E6 was created by transfecting A673BrdU with HPV 16 E6 using the reagent Lipofectamine (Boehringer Mannheim), according to the manufacturer's speci®cations. The HPV plasmids were provided by Dr P Howley's laboratory (Harvard, Cambridge, MA) . SAOS-2 cells were grown in McCoys 5A media supplemented with 15% fetal bovine serum. NHF-16 E6 and NHF 16 E7 cell lines were provided by B Burkhart and were created by infection with retroviral vectors provided by Dr D Galloway (Fred Hutchinson Cancer Research Center, Seattle, Washington) (Halbert et al., 1991) encoding HPV 16 E6 or E7 DNA. All cell lines were maintained in a humidi®ed 378C environment with 5% CO 2 and were routinely tested for Mycoplasma.
Cell fusions
Cell hybrids were generated using polyethylene glycol (PEG) as described (Weissman and Stanbridge, 1980) . Selection was carried out as previously described and colonies were picked after 2 ± 3 weeks. Three independent clones, designated P1, P2, and P3, were selected from each fusion for further characterization. Con®rmation of the hybrid nature of the cell lines was determined by chromosome content and either isozyme pro®le or RFLP markers. Con®rmation that the HHy 79 cell lines represent true hybrids is shown in Table 3 .
Sequence and SSCP analysis of p53 DNA was ampli®ed by polymerase chain reaction (PCR) using previously described primers (Mashiyama et al., 1991) ¯anking the exon regions. The PCR conditions used were as follows: one cycle at 948C for 5 min without Taq or dNTPS, 30 cycles with dNTPs and Taq at 948C for 1 min, 608C for 30 s, 70 8C for 30 s. The ®nal cycle consisted of a 5 min incubation at 728C to complete all ampli®cation products. Single strand conformational polymorphism (SSCP) analysis was used to screen all exons for variables consistent with mutation. For SSCP analysis, DNA samples were radiolabelled during PCR ampli®cation with [
32 P]-a-dCTP. The samples were electrophoresed on an MDE gel (FMC corporation, Rockland, ME) and the gels exposed to Kodak XAR ®lm at 7708C. Sequencing of the highly conserved exons 4 ± 9 was performed with the Cycle Sequencing kit (US Biological, Cleveland, OH). Following ampli®cation, the DNA fragments were gel puri®ed and used as a template for cycle sequencing.
Northern analysis
Approximately 1 ± 5610 6 cells were washed with phosphate-buered saline (PBS) and lysed with guanidine isothiocyanate, from which the total RNA was isolated according to the manufacturer's protocol (Qiagen). Total RNA (10 mg) was electrophoresed in a 1% formaldehyde agarose gel. The gels were transferred onto nylon membranes (Magna nylon membrane, MSI) by capillary action and then u.v. crosslinked in a stratalinker (Stratagene). Blots were prehybridized for 1 h at 668C in prehybridization solution (Quickhybe, Stratagene) and hybridized for 1 ± 2 h at the same temperature. Washes were performed as follows: Two 15 min washes in 26SSC/ 0.1% SDS at 428C; two 15 min washes in 0.16SSC/0.1% SDS at 608C; and if needed to reduce background, a ®nal 20 min wash in 0.1% SSC/0.5% SDS at 688C. Equal RNA loading was veri®ed by probing with B-Actin. Probes were prepared by random priming (Boehringer Mannheim) the gel puri®ed (Qiagen) cDNA inserts, labeled with [
32 P]-adCTP, and puri®ed by twice passing through a G-50 sepharose column (5 Prime-3 Prime, Boulder, Co). The p53 vector p53 SN-3 was provided by Dr B Vogelstein (Johns Hopkins University, Baltimore, MD) and the E6-AP vector was provided by Dr P Howley.
Immuno¯uorescence
Cells were grown on chamber slides, washed with cold PBS, ®xed for 5 min at 720 8C with cold acetone and washed with PBS. The cells were blocked with 5% BSA for 40 min at 378C and incubated with a 1:10 dilution of the HPV 16/18 speci®c murine antibody (Oncogene Science) in 3% BSA 40 min. After 3 ± 4 short washes with PBS, a 1:50 dilution of the rhodamine-based Cy3 conjugated rabbit anti-mouse secondary antibody (Sigma) was added for 30 min in 1% BSA. The slides were mounted with Gel/ Mount (Biomeda), and viewed under a Leitz¯uorescence scope, using the appropriate ®lters.
p53 Western analysis 1 ± 5610 6 cells were grown to approximately 80% con¯uence and solubilized in 0.8 mL of an NP-40 based lysis buer (20 mM Tris, pH 7.4, 250 mM NaCl, 1.0% NP-40, 1 mM EDTA, 50 mg/ml leupeptin, 30 mg/ml aprotinin, and 1 mM PMSF). Following a 30 min incubation on ice, the lysates were scraped, vortexed, and clari®ed by centrifugation at 14 000 r.p.m for 30 min at 48C. Protein quantitation was determined with the BCA protein assay system (Pierce). Fifteen mg of total protein was boiled in SDS Laemmli buer and fractionated on a 10% polyacrylamide gel. Immuno-anity human puri®ed p53, overexpressed in Sf9 cells, was kindly provided by Dr J Selkirk (NIEHS, RTP, NC), and used as a p53 standard. The gel was transferred onto nitrocellulose membrane (MSI, Westboro, MA), blocked with 10% milk overnight, and incubated for 2 h with a 1:1000 dilution of DO-1 antibody (Santa Cruz Biotech.) in Tris-buered saline (TBS) containing 0.1% Tween 20. Following several washes in TBST (Tween 0.3%), a 1:7500 dilution of horseradish peroxidase conjugated rabbit anti-mouse secondary antibody (Amersham) was added for 40 min. After the ®nal washes, immunoreactivity of the blots was detected using ECL reagents (Amersham). The amount of total protein used for Western analysis was previously determined to be within the linear range of this assay.
p53 half-life determination 1 ± 5610 6 cells were washed with PBS and incubated in methionine/cysteine free RPMI medium (Gibco BRL) containing 5% dialyzed fetal bovine serum for 1 h. For metabolic labelling, 3 ml of 0.15 mCi/ml (EXPRE 35 S 35 S, Dupont) was added to T75¯asks for 30 min. After the labelling period, cells were washed and either lysed immediately or chased with RPMI medium to which a ®vefold excess of unlabelled methionine/cysteine was added, for the indicated times. The lysates were precleared by centrifugation for 30 min and then further precleared with protein-A beads (Sigma) that were sequentially coated with rabbit anti-mouse antibody (Oncogene Science), followed by a nonspeci®c antibody of the same IgG subclass as the p53 speci®c antibody as described (Johnson et al., 1994) . The immunoprecipitations were performed with 2 mg of the p53 speci®c antibody DO-1 (Santa Cruz Biotech.) which had been previously bound to protein-A beads (Pierce) coated with rabbit anti-mouse antibody. Equal TCA counts of lysate were immunoprecipitated overnight at 48C. The immunoprecipitates were washed three times in wash buer (20 mM Tris, pH 7.4, 150 mM NaCl, 1.0% NP-40, and 0.1% SDS) and twice in PBS before being boiled in SDS sample buer and separated on a 10% polyacrylamide gel. The gel was fixed for 30 min (10% methanol, 10% acetic acid), enhanced (Amplify, Amersham) dried, and exposed to ®lm (Hyper®lm, Amersham). Radiolabelled p53 was quantitated using phosphorimage analysis for calculation of halflife. The half-life analysis for each cell line was repeated at least twice, with similar results.
p21 induction
Approximately 2 ± 5610 5 cells were grown in duplicate in six well plates. One set was exposed to 450 Rads of irradiation (IR) provided by a cesium source. A second set of nonirradiated control cells served as a comparison for induction. Eighteen hours post IR, both sets of cells were lysed in 250 ml lysis buer and treated as previously described. Seventy mg of total protein was fractionated on a 15% polyacrylamide gel, transferred to nitrocellulose, blocked in 3% milk, and incubated overnight with a 1:100 dilution of p21 antibody (Oncogene Science) overnight. The blots were washed, incubated with the appropriate secondary antibody, and developed for Western analysis as described.
